bioshares report, page-24

"Speculative Buy – Class B
These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening."

I don`t think it is the cash position and the Board may or may not need strengthening.

Must be close to Spec buy "A"

"Speculative Buy – Class A
These stocks will have more than one technology, product or
investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky than other biotech stocks"

Re Metabolic, time for DK to get some traction with this.

Nice to see you added

Cheers